Recombinant Human Lgr5/GPR49 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Lgr5/GPR49 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human R‑Spondin 3 (Catalog # 3500-RS/CF) is coated at 0.5 μg/mL, Recombinant Human Lgr5/GPR49 Fc Chimera binds with an apparent K_d <0.1 nM. Measured by its ability to inhibit Topflash reporter activity in HEK293T human embryonic kidney cells. The ED₅₀ for this effect is 1.5-7.5 µg/mL in the presence of 20 ng/mL Recombinant Human R‑Spondin 2 (Catalog # 3266-RS) and 5 ng/mL Recombinant Mouse Wnt‑3a (Catalog # 1324-WN).
• Source: Chinese Hamster Ovary cell line, CHO-derived human Lgr5/GPR49 protein
  

  Human LGR-5/GPR49 (Gly22-Ile560) Accession # O75473	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: O75473
• N-terminal Sequence: Gly22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: LGR5
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 87 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-110 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Lgr5/GPR49 Fc Chimera Protein, CF

• FEX
• G protein-coupled receptor 49
• GPR49
• GPR49G-protein coupled receptor HG38
• GPR67
• G-protein coupled receptor 49
• G-protein coupled receptor 67
• GRP49
• HG38
• leucine-rich repeat containing G protein-coupled receptor 5
• leucine-rich repeat-containing G protein-coupled receptor 5
• leucine-rich repeat-containing G-protein coupled receptor 5
• Lgr5
• MGC117008
• orphan G protein-coupled receptor HG38

Background

Lgr5 (leucine-rich repeat G-protein coupled receptor 5), also called GPR49, is a seven-transmembrane glycoprotein receptor in the Lgr family of cell surface receptors (1, 2). While this family includes receptors for hormones such as LH, FSH, TSH, and HCG, the subfamily comprising Lgr4, Lgr5, and Lgr6 are G-protein independent mediators of the potentiating effect of R-Spondins on Wnt signaling (1-6). Lgr5 binds and forms complexes with R-Spondins, Frizzled Wnt receptors and LRP Wnt coreceptors (3-5). It acts at least in part by enhancing Wnt-dependent LRP phosphorylation, internalization of LRPs, and accumulation of beta -catenin (3-5). Human Lgr5 cDNA encodes 907 amino acids (aa), including a long N-terminal extracellular domain (ECD, aa 22-561) with 16-17 LRR domains that mediate ligand interaction (2). The LRR-containing ECD of human Lgr5 shares 90% aa sequence identity with mouse and rat Lgr4, and 50-60% aa identity with human Lgr4 and Lgr6. Lgr5 is expressed by embryonic and adult epithelial stem cells, especially in the intestines, stomach, hair follicles, inner ear and mammary glands (1, 5, 6). Lgr4 is also present in epithelial stem cells, but shows wider expression elsewhere, making Lgr5 the preferred marker for these cells (5). Lgr5⁺ stem cells are sufficient to produce all epithelial cell types of the intestinal crypts in vivo or in vitro, when supported by secreted factors from neighboring Paneth or goblet cells (1, 7). In the embryo, Lgr5 is involved in development of the kidney and craniofacial structures (1). It is up-regulated in stem cells that give rise to cancers such as intestinal, hepatocellular, pancreatic and ovarian carcinomas, and may promote carcinogenesis (6).

1. Barker, N. et al. (2013) Development 140:2484.
2. Hsu, S.Y. et al. (1998) Mol. Endocrinol. 12:1830.
3. Carmon, K.S. et al. (2011) Proc. Natl. Acad. Sci. USA 108:11452.
4. Glinka, A. et al. (2011) EMBO Rep. 12:1055.
5. de Lau, W. et al. (2011) Nature 476:293.
6. Leushacke, M. and N. Barker (2012) Oncogene 31:3009.
7. Sato, T. et al. (2011) Nature 469:415.

Publications for Lgr5/GPR49 (8078-GP)(1)

Publication using 8078-GP

• SJ Mileto, T Jardé, KO Childress, JL Jensen, AP Rogers, G Kerr, ML Hutton, MJ Sheedlo, SC Bloch, JA Shupe, K Horvay, T Flores, R Engel, S Wilkins, PJ McMurrick, DB Lacy, HE Abud, D Lyras Clostridioides difficile infection damages colonic stem cells via TcdB, impairing epithelial repair and recovery from disease Proc. Natl. Acad. Sci. U.S.A., 2020-03-20;0(0):. 2020-03-20 [PMID: 32198200] (Cell Culture, Mouse)

Bioinformatics

• Gene Symbol: LGR5
• Uniprot:
  • O75473(Human)